CTOs on the Move

inVentiv Clinical Solutions

www.inventivclinical.com

 
inVentiv Clinical Solutions is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Celera Corporation

Celera Corporation (Celera) is a healthcare business delivering personalized disease management through a combination of products and services. The Company operates in three segments: a clinical laboratory testing service business (Lab Services), a

HBP

Hudson Botanical Processing is a full-service cannabis manufacturing company serving the operational needs of the cannabis industry. They work with industry-leading cannabis brands to produce and distribute the highest quality products in Massachusetts.

Calvary Healing Center

About Calvary Center: Residential/Inpatient/Full Medical Detox/IOP/PHP Treatment for Alcohol, Drugs and Problem Gambling Calvary Addiction Recovery Centers treatment program is for men and women, 18 years and older, who are struggling with substa...

Ipsen

Ipsen S.A. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

KemPharm

KemPharm is a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs that are designed to be improved versions of widely prescribed, approved drugs. Developing and encouraging a unique creativity, leveraged throughout the process of scientific discovery is the foundation of our corporate culture. At KemPharm we employ our Ligand Activated Therapy (LAT™) platform technology to create prodrugs that are new molecules which can improve one or more of the attributes of approved drugs, such as susceptibility to abuse, bioavailability and safety. We create new prodrugs by chemically attaching one or more molecules, or ligands, to an FDA-approved parent drug. When combined with the parent drug, our ligands create prodrugs designed to have improved drug attributes while maintaining efficacy equivalent to the parent drug. Once administered, targeted human metabolic processes, such as those in the GI tract, separate the ligand from the prodrug and release the parent drug, which can then exert its therapeutic effect. KemPharm has employed its LAT™ prodrug platform to create a diverse pipeline of prodrug therapeutics that target large market opportunities in pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system indications.